{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":2000,"summary":"Hosted by Corey with the Story, Business News Today is your daily source for the latest headlines and stories shaping the world of business, finance, and the global economy. From market trends and corporate earnings to startups, entrepreneurship, technology, real estate, consumer trends, and economic policy, we bring you the business news that matters most—in just a few minutes. Whether you're an entrepreneur, investor, executive, business owner, or simply someone who wants to stay informed, Business News Today delivers clear, concise updates to help you understand the forces shaping the economy and the future of business. Business News Today — Business news, all in one place. Powered by AI.","last_synced_at":"2026-09-17T06:21:31.382927+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"BioMarin's Q1: Mixed Results, Upgraded Guidance","slug":"biomarin-s-q1-mixed-results-upgraded-guidance","published_at":"2026-05-14T01:01:42+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/biomarin-s-q1-mixed-results-upgraded-guidance","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/3d485ea9-9e1a-47e8-a40f-037e1f1fcddd.mp3","audio_url":"https://api.fastcast.ai/audio/3d485ea9-9e1a-47e8-a40f-037e1f1fcddd.mp3","summary":"BioMarin Pharmaceuticals Q1 earnings missed expectations with revenue at $766.2M, up 2.8% YoY but short of $776M forecast, and adjusted EPS at $0.76, missing $0.91 estimate due to manufacturing issues and Amicus acquisition costs. Margins dropped to 16.9% from 30% last year. The company raised full-year revenue guidance to $3.88B, up 14.8% from before, but trimmed adjusted EPS to $4.95. Theyre focusing on Amicus integration, new drugs, and clinical data for upcoming products. Margin recovery and regulatory moves could drive stock momentum. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/ad7d7e64420f3557","meta_description":"BioMarin Pharmaceuticals Q1 earnings missed expectations with revenue at $766.2M, up 2.8% YoY but short of $776M forecast, and adjusted EPS at $0.76, miss…","key_points":[],"chapters":[],"topics":[],"duration_seconds":108,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/biomarin-s-q1-mixed-results-upgraded-guidance/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/biomarin-s-q1-mixed-results-upgraded-guidance.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}